| | Total | value | Total | value | Total | value | | MACC1 | c-Met | Cyclin D1 | | Positive 92 (53.5%) | Negative 80 (46.5%) | Positive 98 (57.0%) | Negative 74 (43.0%) | Positive 72 (41.9%) | Negative 100 (58.1%) |
| | Age | | | | | | | | | | | <60 (, 40.7%) | 43 (25.0%) | 27 (15.7%) | | 45 (26.2%) | 25 (14.5%) | | 35 (20.3%) | 35 (20.3%) | | | ≥60 (, 59.3%) | 49 (28.5%) | 53 (30.8%) | 0.08 | 53 (30.8%) | 49 (28.5%) | 0.11 | 37 (21.5%) | 65 (37.8%) | 0.07 | | Gender | | | | | | | | | | | Male (, 68.6%) | 61 (35.5%) | 57 (33.1%) | | 66 (38.4%) | 52 (30.2%) | | 48 (27.9%) | 70 (40.7%) | | | Female (, 31.4%) | 31 (18.0%) | 23 (13.4%) | 0.47 | 32 (18.6%) | 22 (12.8%) | 0.68 | 24 (14.0%) | 30 (17.4%) | 0.64 | | Ethnicity | | | | | | | | | | | Han (, 33.7%) | 33 (19.2%) | 25 (14.5%) | | 41 (23.8%) | 17 (9.9%) | | 23 (13.4%) | 35 (20.3%) | | | Kazakh (, 66.3%) | 59 (34.3%) | 55 (32.0%) | 0.52 | 57 (33.1%) | 57 (33.1%) | 0.01 | 49 (28.5%) | 65 (37.8%) | 0.16 | | Tumor location | | | | | | | | | | | Upper (, 3.5%) | 4 (2.3%) | 2 (1.2%) | | 4 (2.3%) | 2 (1.2%) | | 3 (1.7%) | 3 (1.7%) | | | Middle (, 55.8%) | 48 (27.9%) | 48 (27.9%) | | 51 (29.7%) | 45 (26.2%) | | 40 (23.3%) | 56 (32.6%) | | | Lower (, 40.7%) | 40 (23.3%) | 30 (17.4%) | 0.53 | 43 (25.0%) | 27 (15.7%) | 0.50 | 29 (16.9%) | 41 (23.8%) | 0.92 | | Tumor size | | | | | | | | | | | <3 cm (, 29.7%) | 20 (11.6%) | 31 (18.0%) | | 25 (14.5%) | 26 (15.1%) | | 28 (16.3%) | 23 (13.4%) | | | ≥3 cm (, 70.3%) | 72 (41.9%) | 49 (28.5%) | 0.02 | 73 (42.4%) | 48 (27.9%) | 0.17 | 44 (25.6%) | 77 (44.8%) | 0.02 | | Degree of differentiation | | | | | | | | | | | Poor (, 23.8%) | 25 (14.5%) | 16 (9.3%) | | 25 (14.5%) | 16 (9.3%) | | 16 (9.3%) | 25 (14.5%) | | | Moderate (, 52.4%) | 41 (23.8%) | 49 (28.5%) | | 45 (26.2%) | 45 (26.2%) | | 38 (22.1%) | 52 (30.2%) | | | Well (, 23.8%) | 26 (15.1%) | 15 (8.7%) | 0.09 | 28 (16.3%) | 13 (7.6%) | 0.12 | 18 (10.5%) | 23 (13.4%) | 0.90 | | Lymph node metastasis | | | | | | | | | | | Negative (, 70.3%) | 66 (38.4%) | 55 (32.0%) | | 69 (40.1%) | 52 (30.2%) | | 54 (31.4%) | 67 (39.0%) | | | Positive (, 29.7%) | 26 (15.1%) | 25 (14.5%) | 0.67 | 29 (16.9%) | 22 (12.8%) | 0.98 | 18 (10.5%) | 33 (19.2%) | 0.26 | | Invasive depth | | | | | | | | | | | Mucosa (, 2.9%) | 3 (1.7%) | 2 (1.3%) | | 3 (1.7%) | 2 (1.2%) | | 1 (0.6%) | 4 (2.3%) | | | Muscularis (, 45.3%) | 38 (22.0%) | 40 (23.3%) | | 46 (26.7%) | 32 (18.6%) | | 33 (19.2%) | 45 (26.2%) | | | Full thickness (, 51.8%) | 51 (29.7%) | 38 (22.0%) | 0.52 | 49 (28.5%) | 40 (23.3%) | 0.87 | 38 (22.1%) | 51 (29.7%) | 0.58 | | AJCC stage | | | | | | | | | | | IA+B (, 7.6%) | 11 (6.4%) | 2 (1.2%) | | 10 (5.8%) | 3 (1.7%) | | 6 (3.5%) | 7 (4.1%) | | | IIA+B (, 65.7%) | 56 (32.6%) | 57 (33.1%) | | 59 (34.3%) | 54 (31.4%) | | 48 (27.9%) | 65 (37.8%) | | | IIIA+B (, 18.6%) | 18 (10.5%) | 14 (8.1%) | | 21 (12.2%) | 11 (6.4%) | | 12 (7.0%) | 20 (11.6%) | | | IVA+B (, 8.2%) | 7 (4.1%) | 7 (4.1%) | 0.12 | 8 (4.7%) | 6 (3.5%) | 0.25 | 6 (3.5%) | 8 (4.7%) | 0.95 | | Vascular invasion | | | | | | | | | | | Negative (, 82.0%) | 76 (44.2%) | 65 (37.8%) | | 79 (45.9%) | 62 (36.0%) | | 59 (34.3%) | 82 (47.7%) | | | Positive (, 18.0%) | 16 (9.3%) | 15 (8.7%) | 0.82 | 19 (11.0%) | 12 (7.0%) | 0.59 | 13 (7.6%) | 18 (10.5%) | 0.99 | | Nerve invasion | | | | | | | | | | | Negative (, 78.5%) | 77 (44.8%) | 58 (33.7%) | | 78 (45.3%) | 57 (33.1%) | | 55 (32.0%) | 80 (46.5%) | | | Positive (, 21.5%) | 15 (8.7%) | 22 (12.8%) | 0.08 | 20 (11.6%) | 17 (9.9%) | 0.69 | 17 (9.9%) | 20 (11.6%) | 0.57 | | Hematogenous metastasis | | | | | | | | | | | Negative (, 84.9%) | 77 (44.8%) | 69 (40.1%) | | 79 (45.9%) | 67 (39.0%) | | 58 (33.7%) | 88 (51.2%) | | | Positive (, 15.1%) | 15 (8.7%) | 11 (6.4%) | 0.64 | 19 (11.0%) | 7 (4.1%) | 0.07 | 14 (8.1%) | 12 (7.0%) | 0.18 |
|
|
